
DIRECTIONS

THE NATIONAL HEALTH SERVICE ACT 2006

The Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

Citation, commencement, application and interpretation

1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020, and—

- (a) apart from directions 2 and 4, come into force immediately after they are signed;
- (b) directions 2 and 4 come into force on 1st April 2020.

(2) These Directions apply in relation to England.

(3) In these Directions, “the 2013 Directions” means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(b).

Amendment of direction 5 of the 2013 Directions

2.—(1) Direction 5 of the 2013 Directions(c) (MUR services: ongoing conditions of arrangements) is amended as follows.

(2) In paragraph (1), for sub-paragraph (g) substitute—

“(g) at least 70% of the MUR service consultations carried out by P—

- (i) in the period beginning on 1st April 2020 and ending at the end of 30th June 2020, are to be carried out with patients who are in one or both of the national target groups set out in paragraphs 1 and 2 of Schedule 1, and

(a) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) (“the 2012 Act”), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65.

(b) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013, signed on 16th September 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013, which also revoked the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2014, signed on 12th March 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2015, signed on 15th September 2015; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2016, signed on 30th August 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2016, signed on 30th November 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2017, signed on 29th August 2017; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2018, signed on 8th March 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2018, signed on 31st August 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2019, signed on 22nd August 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 4) Directions 2019, signed on 25th October 2019.

(c) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019.

- (ii) in the period beginning on 1st July 2020 and ending at the end of 31st March 2021, are to be carried out with patients who are in the national target group set out in paragraph 1 of Schedule 1;”.

Amendment of direction 14 of the 2013 Directions

3.—(1) Direction 14 of the 2013 Directions(a) (enhanced services provided by pharmacy contractors) is amended as follows.

(2) In paragraph (1), in sub-paragraph (u)—

- (a) after “cases of urgency” insert “or whilst a disease is or in anticipation of a disease being imminently pandemic and a serious risk or potentially a serious risk to human health”; and
- (b) in paragraph (ii), for from “regulation 225(1)” to “patient’s request)” substitute “regulation 225 or 226 of the Human Medicines Regulations 2012(b) (which relate to emergency sale etc. by pharmacist either at patient’s request or while a disease is or in anticipation of a disease being imminently pandemic and a serious risk or potentially a serious risk to human health)”.

4. Direction 3 of the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019, is revoked.

Signed by authority of the Secretary of State for Health and Social Care



6th March 2020

Jeannette Howe
Head of Pharmacy
Department of Health and Social Care

(a) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013.

(b) S.I. 2012/1916. Regulation 225 has been amended by S.I. 2014/490.